Anti-Rheumatic Drugs - United Arab Emirates

The market of Anti-Rheumatic Drugs market in the United Arab Emirates is anticipated to witness a significant increase in revenue, with projections indicating it will reach US$49.85m by the year 2024.
Moreover, this sector is expected to maintain a steady growth rate of 1.92% annually from 2024 to 2029, ultimately leading to a market volume of US$54.81m by the end of 2029.
When compared to other countries globally, United States is forecasted to generate the highest revenue in this market, with an estimated value of US$34.70bn by 2024.
The demand for anti-rheumatic drugs in the United Arab Emirates is rising due to the increasing prevalence of rheumatic diseases in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The demand for Anti-Rheumatic Drugs in the United Arab Emirates has been on the rise in recent years.

Customer preferences: The population in the United Arab Emirates is relatively young, with a high prevalence of autoimmune diseases. The preference for early diagnosis and treatment of these conditions has led to a surge in demand for Anti-Rheumatic Drugs. Additionally, the high prevalence of obesity and sedentary lifestyles has led to an increase in musculoskeletal disorders, further driving the demand for these drugs.

Trends in the market: The Anti-Rheumatic Drugs market in the United Arab Emirates is witnessing a shift towards biologic therapies. Patients are increasingly opting for biologic drugs due to their higher efficacy and lower toxicity compared to traditional disease-modifying antirheumatic drugs (DMARDs). The market is also witnessing a trend towards combination therapies, with physicians prescribing a combination of DMARDs and biologic agents.

Local special circumstances: The healthcare sector in the United Arab Emirates is growing rapidly, with the government investing heavily in the development of healthcare infrastructure. The country has a well-developed healthcare system, with a high concentration of hospitals and clinics. Additionally, the country has a high prevalence of autoimmune diseases, which has led to a high demand for Anti-Rheumatic Drugs.

Underlying macroeconomic factors: The United Arab Emirates has a high per capita income and a strong economy, which has enabled the population to afford expensive biologic therapies. The country has a well-developed healthcare system, which has led to the early diagnosis and treatment of autoimmune diseases. The government's focus on developing healthcare infrastructure has also contributed to the growth of the Anti-Rheumatic Drugs market in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.